Back
Open Access

Benefits and evolving insights on SGLT2i in the spectrum of LVEF: can we set priorities?

Session: When to start using SGLT2i in HFrEF? Initiating guideline-recommended treatment options
Topic: Treatment
Speaker: Professor C. Lam (Singapore, SG)
Sponsored by PACE-CME – Supported by an unrestricted educational grant from AstraZeneca
Event: Heart Failure 2022

Congress Presentation

About the speaker

Professor Carolyn Sp Lam

Duke-NUS Graduate Medical School Singapore, Singapore (Singapore)
147 presentations
50 followers

3 more presentations in this session

The clinical challenges of initiating guideline-recommended therapy in HFrEF.

Speaker: Professor J. McMurray (Glasgow, GB)

Access
Slides
Video
Thumbnail

Expanding evidence on SGLT2i: where are we now and what can we expect?

Speaker: Professor S. Solomon (Boston, US)

Access
Slides
Video
Thumbnail

Expert panel: What are the implications for our practice?

Speaker: Professor J. McMurray (Glasgow, GB) Professor C. Lam (Singapore, SG) Professor S. Solomon (Boston, US)

Access
Slides
Video
Thumbnail

Access the full session

When to start using SGLT2i in HFrEF? Initiating guideline-recommended treatment options

Speakers: Professor C. Lam, Professor J. McMurray, Professor S. Solomon, Professor J. McMurray, Professor C. Lam...
Access
Video
Thumbnail

About the event

Image

Heart Failure 2022

21 May - 24 May 2022

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb